Empagliflozin 10 mg

Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes

Empagliflozin for No-reflow Phenomenon in PCI for STEMI

Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease

SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial

Empagliflozin in Hypertrophic Cardiomyopathy

Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension

Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease

Empagliflozin in Patients With Cirrhosis and Ascites

Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure

Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial

Empagliflozin Reversal of Arterial StiffnEss in Aging

Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients

Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease

Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension

Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT

Safety and Efficacy of Empagliflozin in Hemodialysis

Empagliflozin on Patients With Preserved Heart Failure

Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)

Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines